World Ovarian Cancer Day: CISPOLY Harnesses Methylation Technology for Earlier Detection of the 'Silent Killer'
May 8th is World Ovarian Cancer Day. Ovarian cancer is known as the "king of gynecologic cancers"—due to its insidious early symptoms, approximately 70% of patients are already at intermediate to advanced stages at diagnosis, with a five-year survival rate below 50%. Early detection has become the key to fighting this disease.
I. Pay Attention to Body Signals and Detect Risks Early
The ovaries are located deep within the pelvis, making early lesions difficult to detect. The following symptoms warrant particular vigilance: persistent abdominal bloating and pain, decreased appetite with increased abdominal girth, frequent urination and urgency, changes in bowel habits, and unexplained fatigue or weight loss.
While these symptoms are not necessarily indicative of ovarian cancer, they should be taken seriously if persistent. The core challenge in ovarian cancer prevention and treatment lies in how to identify risk earlier, before symptoms become apparent.
II. Methylation Detection Provides a New Early Screening Pathway
The NMPA Class III-certified non-invasive ovarian cancer CDO1/HOXA9 methylation detection achieves early "molecular foresight" by capturing specific methylation signals in blood, providing women with a non-invasive and convenient screening option.
III. Early Detection Safeguards Health
World Ovarian Cancer Day reminds us that paying attention to ovarian cancer is not only about one disease—it is about the long-term health of every woman. With the development of molecular detection technology, early diagnosis of ovarian cancer is undergoing breakthroughs.
CISPOLY's methylation detection builds a defense for women's health through technological power, enabling earlier detection of the "silent" ovarian cancer risk.
Kind reminder: This article is educational health content and cannot replace medical diagnosis and treatment recommendations. If you experience persistent abdominal bloating, pain, decreased appetite, frequent urination, or other abnormal symptoms, please promptly visit a qualified medical institution.
Beijing Origin-Poly Co., Ltd. is a technology enterprise driven by innovation and committed to health. As a pioneer in the field of early diagnosis of gynecologic tumors, CISPOLY has developed early detection products for cervical cancer, endometrial cancer, ovarian cancer and other gynecologic malignancies based on proprietary technologies and patent-protected biomarkers, filling gaps in this field.
As women's awareness of their own health continues to grow, the women's health market holds tremendous potential. Beyond the gynecologic tumor early screening and diagnosis product line, CISPOLY will continue to establish additional women's health-related product pipelines, striving to become a technology innovation leader in the women's health market.